**Insulin Detemir Therapy in Type 2 Diabetes: Outcomes from the South India Cohort of the A1chieve Study**
The A1chieve study, a global, non-interventional, 24-week observational trial, evaluated the real-world use of insulin analogues in patients with type 2 diabetes mellitus (T2DM). This report presents data from the South India cohort focusing on insulin detemir therapy, one of the most commonly prescribed basal insulin analogues. A total of 1,001 patients were included in this analysis—865 (86.4%) insulin-naïve and 136 (13.6%) insulin-experienced—enrolled across multiple centers in southern India.
At baseline, both groups exhibited suboptimal glycaemic control. The mean HbA1c was 9.6% in insulin-naïve patients and 9.2% in insulin users, reflecting persistent hyperglycemia despite prior oral glucose-lowering drug (OGLD) therapy. Patients had been managed with OGLDs for an average of 6–11 years, indicating long-standing disease burden and inadequate glucose control.CDH16 Protein Biological Activity
After 24 weeks of treatment with insulin detemir ± OGLDs, significant improvements were observed. In insulin-naïve individuals, HbA1c decreased from 9.6% to 8.1%, a reduction of -1.6%. Insulin users achieved a similar improvement, with HbA1c declining from 9.2% to 7.8%, a change of -1.3%. Fasting plasma glucose (FPG) fell from 10.8 mmol/L to 7.8 mmol/L, and postprandial glucose (PPPG) dropped from 16.2 mmol/L to 10.5 mmol/L, demonstrating effective day-long glucose management.
Hypoglycaemia remained a key safety concern, yet the incidence was remarkably low. In insulin-naïve patients, hypoglycaemia rates declined from 1.0 to 0.2 events per patient-year, while insulin users saw a reduction from 2.3 to 0.7 events per patient-year. Notably, no major hypoglycaemic episodes or serious adverse drug reactions (SADRs) were reported during the study period, underscoring the excellent safety profile of insulin detemir in this population.
Body weight showed a modest but consistent decline, decreasing from 70.8 kg to 69.8 kg in insulin-naïve patients and from 70.7 kg to 69.4 kg in insulin users. This contrasts with the typical weight gain associated with conventional insulin therapy, highlighting insulin detemir’s favourable metabolic effect.Celecoxib custom synthesis Quality of life, measured via the visual analogue scale (VAS), improved significantly—from 62.2 to 74.4 in insulin-naïve individuals and from 57.PMID:35114376 3 to 70.3 in insulin users—indicating enhanced well-being and treatment satisfaction.
Insulin dosing was stable over time, with daily doses increasing slightly from 14.9 U to 16.5 U in insulin-naïve patients and from 18.0 U to 19.3 U in insulin users. These adjustments reflect appropriate titration without overtreatment. Lipid profiles improved, with LDL-C levels decreasing and a higher proportion of patients achieving targets below 2.5 mmol/L. Systolic blood pressure also declined, from 139.9 mmHg to 128.8 mmHg, contributing to reduced cardiovascular risk.
In conclusion, insulin detemir demonstrated strong efficacy in improving glycaemic control in South Indian patients with T2DM, including those newly initiating insulin therapy. Its low risk of hypoglycaemia, neutral or beneficial impact on body weight, and positive effect on quality of life make it a preferred choice for basal insulin replacement. These findings support the integration of insulin detemir into routine clinical practice, particularly in populations where safety and tolerability are paramount.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
**Background**
Metabolic disorders, such as obesity and muscle atrophy, as well as various malignancies, remain significant challenges in global healthcare. The regulation of energy homeostasis and cellular proliferation often involves the activation of key signaling pathways, including the PI3K/Akt and AMPK pathways, as well as the modulation of Sirt1 and mitochondrial oxidative phosphorylation (OXPHOS). Targeting these pathways provides a strategic approach to treating muscle wasting, obesity, and tumor growth. In this context, we will introduce a potent prenyl flavonoid derived from the hop spike Humulus lupulus – 8-Prenylnaringenin.
**Definition**
8-Prenylnaringenin is an orally active prenyl flavonoid that acts as a SIRT1 activator and exhibits significant 8-Prenylnaringenin Biological Activity across various physiological systems. It is characterized by the 8-Prenylnaringenin Formula C20H20O5 and a molecular weight of 340.37.
**In Vitro and In Vivo Studies**
The 8-Prenylnaringenin Description highlights its multi-target efficacy. In 8-Prenylnaringenin In Vitro studies, the compound demonstrated strong antiproliferative effects against human colon cancer HCT-116 cells with an IC50 value of 23.83 μg/mL. In human glioblastoma U-118 MG cells, it showed cytotoxicity with an IC50 of approximately 138 μM, which was higher than that observed in normal BJ fibroblasts (IC50 = 172 μM). Furthermore, 8-Prenylnaringenin (0.001-20 μM; 48 h) reduced ROS production and SOD activity in MCF-7 breast cancer cells, while upregulating Sirt1 and OXPHOS complexes II, III, and V. It also inhibited BME cell invasion (IC50: 3-10 μM) and dose-dependently inhibited angiogenesis induced by bFGF and VEGF.
In 8-Prenylnaringenin In Vivo experiments, the compound showed significant therapeutic potential. In C57/BL6 mice, oral administration (0.00005-0.0005% wt/wt in diet) promoted recovery from immobilization-induced disuse muscle atrophy by activating the Akt phosphorylation pathway. In C57BL/6J male mice fed a high-fat diet, 8-Prenylnaringenin (0.0005%-0.005% wt/wt; 8 weeks) prevented obesity and fat accumulation in white adipose tissue by promoting adiponectin secretion and activating the AMPK pathway, which subsequently regulated SREBP-1 and PGC-1α expression. Additionally, in ovariectomized Sprague-Dawley rats, it suppressed serum LH/FSH levels and stimulated uterine weight. Regarding 8-Prenylnaringenin Cancer research, its ability to inhibit tumor cell proliferation and angiogenesis makes it a valuable tool for oncology studies. In conclusion, 8-Prenylnaringenin is a versatile prenyl flavonoid with potent activities in metabolic regulation and anticancer research.
Keywords
8-Prenylnaringenin, 53846-50-7, PI3K, Akt, AMPK, Sirtuin, Reactive Oxygen Species (ROS), SOD, Phosphoinositide 3-kinase, PKB, Protein kinase B, AMP-activated protein kinase, Superoxide Dismutase, Inhibitor, inhibitor, inhibit
References
[1] Koosha S, et al. Antiproliferative and apoptotic activities of 8-prenylnaringenin against human colon cancer cells. Life Sci. 2019 Jul 3:116633.
[2] Mukai R, et al. 8-Prenylnaringenin promotes recovery from immobilization-induced disuse muscle atrophy through activation of the Akt phosphorylation pathway in mice. Am J Physiol Regul Integr Comp Physiol. 2016 Dec 1;311(6):R1022-R1031.
[3] Stompor M, et al. In Vitro Effect of 8-Prenylnaringenin and Naringenin on Fibroblasts and Glioblastoma Cells-Cellular Accumulation and Cytotoxicity. Molecules. 2017 Jun 30;22(7).
[4] Blanquer-Rosselló MM, et al. Effect of xanthohumol and 8-prenylnaringenin on MCF-7 breast cancer cells oxidative stress and mitochondrial complexes expression. J Cell Biochem. 2013 Dec;114(12):2785-94.
[5] Pepper MS, et al. 8-prenylnaringenin, a novel phytoestrogen, inhibits angiogenesis in vitro and in vivo. J Cell Physiol. 2004 Apr;199(1):98-107.
[6] Okada F, et al. 8-Prenylnaringenin suppresses obesity in high-fat diet-fed C57BL/6J mice via adiponectin secretion. J Clin Biochem Nutr. 2025 Jul;77(1):64-73.
[7] Christoffel J, et al. Effects of 8-prenylnaringenin on the hypothalamo-pituitary-uterine axis in rats after 3-month treatment. J Endocrinol. 2006 Mar;188(3):397-405.
[8] Hoffmann DB, et al. Effects of 8-Prenylnaringenin and Whole-Body Vibration Therapy on a Rat Model of Osteopenia. J Nutr Metab. 2016;2016:6893137.
**Background**
Human Immunodeficiency Virus (HIV) is a retrovirus that attacks the immune system, specifically CD4+ T cells, leading to Acquired Immunodeficiency Syndrome (AIDS). The replication cycle of HIV involves the reverse transcription of viral RNA into DNA, a process that is critical for the integration of the viral genome into the host cell’s DNA. Consequently, targeting the reverse transcription process has been a primary strategy in the development of antiretroviral therapies. Effective inhibition of viral replication is essential to reduce viral load and prevent the progression of the disease. In this context, we will introduce a potent inhibitor of HIV replication – 2′,3′-Dideoxyadenosine.
**Definition**
2′,3′-Dideoxyadenosine is an antiretroviral compound that acts as an inhibitor of HIV replication, demonstrating significant antiviral efficacy against multiple strains of the virus.
**In Vitro Studies**
According to the 2′,3′-Dideoxyadenosine technical information, this compound exhibits broad-spectrum activity against various retroviruses. In 2′,3′-Dideoxyadenosine in vitro assays, it inhibits HIV-1 and simian immunodeficiency virus (SIV) in MT-4 cells with $\text{EC}_{50}$ values of 5.27 $\mu\text{M}$ and 5.3 $\mu\text{M}$, respectively. In human T-lymphocyte CEM cells, it inhibits HIV-1 and HIV-2 with $\text{EC}_{50}$ values of 4 $\mu\text{M}$ and 8 $\mu\text{M}$, respectively. Furthermore, in Molt 4/C8 cells, the $\text{EC}_{50}$ values for HIV-1 and HIV-2 inhibition are 4 $\mu\text{M}$ and 5.5 $\mu\text{M}$, while in C8166 cells, the values are 17 $\mu\text{M}$ and 22 $\mu\text{M}$. Beyond HIV, 2′,3′-Dideoxyadenosine biological activity extends to the inhibition of murine sarcoma virus (MSV) in C3H/3T3 cells with an $\text{EC}_{50}$ of 24 $\mu\text{M}$. Regarding cytotoxicity, the $\text{CC}_{50}$ in human CEM cells is reported to be $> 250 \mu\text{M}$, and in MT-4 cells, it is approximately 890 $\mu\text{M}$, indicating a favorable therapeutic window. In conclusion, 2′,3′-Dideoxyadenosine is a potent antiviral agent effective against HIV-1, HIV-2, and SIV.
Keywords
2′,3′-Dideoxyadenosine, 4097-22-7, HIV, Human immunodeficiency virus, Inhibitor, inhibitor, inhibit
References
Apoptosis, or programmed cell death, is a tightly regulated process essential for maintaining cellular homeostasis and preventing uncontrolled proliferation. In cancer, evasion of apoptosis is a hallmark feature that enables tumor cells to survive despite genetic damage and stress signals. Melittin (MEL), a major component of bee venom, has emerged as a potent inducer of apoptosis in various cancer types, including cervical carcinoma. This study investigates the molecular mechanisms by which melittin triggers apoptosis and induces cell cycle arrest in human cervical cancer CaSki cells.
Treatment with melittin led to a significant reduction in cell viability in a dose- and time-dependent manner, as confirmed by MTT and WST-1 assays. At concentrations ranging from 0.5 to 2 μg/mL, melittin effectively inhibited proliferation without causing substantial toxicity at lower doses, suggesting a therapeutic window. Flow cytometry analysis revealed that melittin induced G2/M phase cell cycle arrest, accompanied by a marked increase in the sub-G1 population, indicative of DNA fragmentation and apoptotic cell death.
Mechanistically, melittin activated key components of the intrinsic apoptotic pathway. Western blot analysis showed a progressive increase in cleaved caspase-9 and caspase-3, along with a decrease in pro-caspase forms. Concurrently, the levels of anti-apoptotic proteins Bcl-2 and Bcl-xL were significantly downregulated, while the pro-apoptotic protein Bax was upregulated. This shift in the Bcl-2/Bax ratio promoted mitochondrial outer membrane permeabilization (MOMP), leading to cytochrome c release into the cytosol. The subsequent formation of the apoptosome complex triggered caspase-9 activation, initiating the execution phase of apoptosis.
Further evidence was provided by caspase activity assays, which demonstrated a strong dose-dependent activation of caspase-3 and caspase-9 following melittin treatment. Pretreatment with pan-caspase inhibitor Z-VAD-FMK significantly attenuated apoptosis, confirming the critical role of caspases in mediating melittin-induced cell death.Pimicotinib site Additionally, melittin induced PARP cleavage, a hallmark of apoptotic execution, further supporting the activation of the caspase cascade.Alogliptin Protocol
In parallel, melittin suppressed the expression of cyclin-dependent kinases (CDKs) and cyclins involved in G2/M transition.PMID:34904508 Specifically, the levels of CDK1, CDK2, cyclin B1, and cyclin A were markedly reduced after melittin exposure. This downregulation disrupted the assembly of functional CDK-cyclin complexes necessary for cell cycle progression, thereby contributing to the observed G2/M arrest. Phosphorylation of retinoblastoma protein (Rb) was also diminished, indicating inhibition of the G1/S transition, although the primary arrest occurred at G2/M.
Immunofluorescence staining revealed nuclear condensation and fragmentation in melittin-treated cells, consistent with apoptotic morphology. Moreover, transmission electron microscopy showed characteristic ultrastructural changes, including chromatin margination and membrane blebbing, further validating apoptosis induction.
These findings demonstrate that melittin exerts dual anticancer effects in CaSki cells: it activates caspase-dependent apoptosis via mitochondrial dysfunction and inhibits cell cycle progression by suppressing CDK/cyclin activity. The selective targeting of these pathways suggests that melittin may overcome resistance mechanisms commonly seen in chemotherapy-resistant cancers. Given its ability to induce apoptosis without affecting normal cells at therapeutic doses, melittin holds promise as a natural agent for cervical cancer therapy. Future studies should focus on optimizing delivery systems and evaluating efficacy in vivo to advance its potential clinical application.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
The development of functional enzymes capable of operating effectively in human physiological environments is a cornerstone of modern biotechnology, particularly in the design of implantable biosensors and biofuel cells. In this context, high-redox potential laccases (HRPLs) from basidiomycetes offer unique advantages due to their ability to catalyze oxygen reduction at high potentials. However, their natural susceptibility to inhibition by hydroxide ions and halides—abundant in blood—has limited their practical use. To overcome these barriers, we engineered a blood-tolerant laccase variant, ChU-B, through iterative directed evolution in Saccharomyces cerevisiae, and subsequently optimized its overexpression in Pichia pastoris for scalable production.
The ChU-B mutant was constructed by fusing the mature laccase domain of PM1 strain CECT 2971 to either native or evolved α-factor prepro-leader sequences. These constructs were cloned under two distinct promoters: PAOX1 (methanol-inducible) and PGAP (constitutive). Initial screening in shake-flask cultures identified the PAOX1-driven construct with the evolved prepro-leader as the most productive. This candidate was then subjected to small-scale fed-batch fermentation in a 500-mL bioreactor, achieving peak laccase activity of 990 ABTS-U/L after 151 hours of induction. Encouraged by these results, the process was scaled up to a 42-L bioreactor system using a 20-L fermentation volume. The final yield reached 43 mg/L of purified recombinant enzyme, marking a 5.4-fold increase over S. cerevisiae-based production (~8 mg/L).
Purification of the ChU-B laccase involved a three-step chromatographic protocol: ammonium sulfate precipitation, anion-exchange (Mono Q), and hydrophobic interaction chromatography (PHE sepharose). The resulting protein was homogeneous, as confirmed by SDS-PAGE and MALDI-TOF mass spectrometry. The molecular weight of the P. pastoris-produced enzyme was determined to be 62,541 Da, consistent with the presence of additional glycosylation compared to the S. cerevisiae version (60,310 Da). Glycosylation levels were estimated at 16% in P. pastoris versus 12% in S. cerevisiae, reflecting differences in post-translational processing between hosts.
Despite higher glycosylation, the enzyme retained full functionality. N-terminal sequencing revealed identical extra extensions (ETEAEF) in both expression systems, indicating incomplete cleavage of the α-factor pro-leader by STE13 protease—a phenomenon observed in both yeasts. This extension did not impair activity but may contribute to secretion efficiency. The pH-activity profile remained unchanged across hosts, with optimal activity at pH 4.0 (ABTS) and pH 5.0 (DMP), and significant residual activity at pH 7.4. Most notably, the ChU-B mutant exhibited exceptional resistance to halide inhibition: I50 values for Cl⁻ exceeded 1000 mM at acidic pH, and F⁻ inhibition was also substantially reduced.Bis(4-tert-butylphenyl)amine Cancer
Kinetic analysis demonstrated that Km values for ABTS and DMP were similar between the two hosts (~0.024 mM and ~0.26 mM, respectively), indicating no loss in substrate affinity.STAT3 Antibody manufacturer However, kcat values were consistently higher in the S.PMID:35086724 cerevisiae-expressed form, suggesting subtle differences in catalytic turnover possibly linked to glycosylation patterns or folding dynamics. Still, the overall catalytic efficiency remained sufficient for biomedical applications.
Functional validation in human plasma and whole blood confirmed the enzyme’s real-world utility. Oxygen consumption rates were measured using a Clark electrode, yielding values of 31 ± 7 min⁻¹ in blood and 27 ± 1 min⁻¹ in plasma—indicating robust activity in complex biological matrices without interference from serum proteins or cellular components. This performance underscores the enzyme’s suitability for integration into miniature biofuel cells and continuous monitoring devices.
In conclusion, the combination of directed evolution in S. cerevisiae followed by high-level expression in P. pastoris provides a scalable, efficient, and reliable platform for producing advanced biocatalysts. The ChU-B laccase exemplifies how rational engineering can transform a naturally sensitive enzyme into a stable, blood-compatible biocatalyst. Its successful production and characterization pave the way for future applications in implantable diagnostics, wearable sensors, and energy-harvesting devices operating within the human body.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
Intrauterine growth restriction (IUGR) is increasingly recognized as a condition with profound implications for fetal metabolic programming, predisposing individuals to insulin resistance, obesity, and cardiovascular disease in adulthood. Central to this process are adipocytokines—bioactive molecules secreted by adipose tissue that regulate energy homeostasis, inflammation, and insulin sensitivity. Among these, adiponectin and leptin play opposing roles: adiponectin exerts anti-inflammatory and insulin-sensitizing effects, while leptin primarily regulates appetite and energy balance but also contributes to immune activation and endothelial dysfunction when dysregulated. This study investigates the maternal-fetal serum levels of adiponectin and leptin in IUGR, small-for-gestational-age (SGA), and appropriate-for-gestational-age (AGA) pregnancies, aiming to clarify their role in metabolic and vascular adaptation during fetal development.
A retrospective cohort analysis was conducted on 140 pregnant women from the University of Padua between January 2011 and March 2013. Participants were stratified into three groups: 37 IUGR (EFW < 10th percentile with abnormal umbilical artery Doppler), 33 SGA (EFW < 10th percentile without Doppler abnormalities), and 70 AGA (EFW ≥ 10th percentile). Blood samples were collected at delivery from both mothers and umbilical cords. Serum concentrations of adiponectin and leptin were measured using radioimmunoassay kits with high analytical precision. Adiponectin levels were determined via Millipore RIA kit (HADP-61HK), with a sensitivity of 1 μg/L and measuring range of 1–240 μg/L. Leptin was assessed using Mediagnost’s streptavidin-coated tube assay, with sensitivity of 0.1 μg/L and a dynamic range of 0.1–64 μg/L. Results revealed a striking imbalance in adipocytokine profiles among IUGR fetuses. Fetal adiponectin levels were significantly lower in IUGR compared to both SGA (p < 0.05) and AGA (p < 0.05) groups, with median values of 134 μg/L versus 197 μg/L and 196 μg/L, respectively. Conversely, fetal leptin levels were markedly elevated in IUGR fetuses (median 7.1 μg/L) compared to SGA (4.3 μg/L) and AGA (4.9 μg/L) (p < 0.05). The adiponectin-to-leptin ratio (A/L ratio), considered a key indicator of metabolic risk, was significantly reduced in IUGR fetuses (median 17.4) compared to SGA (43.5) and AGA (41.3) (p < 0.05). Maternal findings mirrored those in the fetus. Maternal adiponectin was significantly lower in IUGR women (median 45 μg/L) than in SGA (58 μg/L) and AGA (57 μg/L) (p < 0.05). Maternal leptin was highest in IUGR (8.2 μg/L), followed by SGA (8.5 μg/L), and lowest in AGA (5.5 μg/L) (p < 0.05). These results suggest a systemic shift toward a pro-inflammatory and metabolically unfavorable state in IUGR pregnancies. Correlation analyses demonstrated that fetal adiponectin positively correlated with gestational age at delivery (p < 0.05) and birth weight (p < 0.05), indicating its physiological importance in normal fetal development.Triisopropyl Autophagy In contrast, fetal leptin showed a positive correlation with aIMT (p < 0.BCL6 Antibody In Vitro 05), suggesting a direct link between increased leptin and vascular remodeling.PMID:35155866 Furthermore, the A/L ratio exhibited a significant negative correlation with aIMT in IUGR fetuses (p < 0.05), reinforcing the hypothesis that an imbalance between adiponectin and leptin may drive early atherosclerotic changes. The pathophysiological mechanisms underlying these findings involve multiple pathways. Reduced adiponectin impairs insulin signaling and promotes inflammation by failing to suppress macrophage activation and cytokine release. Elevated leptin contributes to oxidative stress, endothelial dysfunction, and increased vascular tone. Together, they create a permissive environment for vascular damage, even in the absence of overt hyperglycemia or hypertension. These results highlight the critical role of adipocytokine dysregulation in the developmental origins of health and disease. The observed imbalance in adiponectin and leptin in IUGR fetuses may represent an adaptive response to nutrient scarcity, but one that carries long-term risks. Early identification of this profile could enable targeted interventions, such as maternal nutritional optimization or postnatal monitoring of metabolic parameters, to mitigate future disease burden. In conclusion, IUGR is associated with a distinct adipocytokine signature characterized by low adiponectin, high leptin, and a reduced A/L ratio. This imbalance correlates with increased vascular thickness and systemic inflammation, suggesting a mechanistic link between fetal metabolic programming and adult-onset cardiovascular disease. Future research should explore whether modulating this axis during pregnancy can improve long-term outcomes for affected offspring.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
Despite the proven safety and efficacy of adeno-associated virus serotype 2 (AAV2) vectors in gene therapy, their clinical application is often limited by dose-dependent immune responses, particularly CD8+ T cell activation against the capsid proteins. This immune reaction becomes prominent at high vector doses—commonly used in systemic delivery for liver-targeted therapies—leading to transgene silencing and potential loss of therapeutic benefit. To address this challenge, we developed a novel class of bioengineered AAV2 vectors through targeted mutagenesis of key serine, threonine, and lysine residues on the capsid surface.
We focused on residues within phosphodegron regions—structural motifs that serve as recognition sites for host kinases and ubiquitin ligases. Phosphorylation of these residues triggers ubiquitination and subsequent proteasomal degradation of incoming viral particles, reducing their transduction efficiency. We hypothesized that mutating these residues would not only enhance intracellular stability but also alter antigenic epitopes, thereby reducing immunogenicity. Using structural modeling and evolutionary conservation analysis, we identified 15 candidate residues across three phosphodegrons: S489, S498, S662, S668, T251, T454, T503, T671, T701, T713, T716, K39, K137, K143, K161, K490, K507, K527, K532, and K544. Single and double mutants were generated using site-directed mutagenesis, with serine/threonine substituted by alanine (S/A, T/A) and lysine replaced by arginine (K/R).
All mutant vectors were packaged into self-complementary EGFP-expressing constructs and purified via iodixanol gradient ultracentrifugation and column chromatography. Physical titers ranged from 1 × 10¹² to 3.Doxycycline hyclate supplier 2 × 10¹² VG/ml, confirming successful packaging with minimal disruption to capsid integrity.HKUST-1 In Vitro In vitro testing in HeLa and HEK-293 cells showed that 11 S/T/A and 7 K/R mutants significantly outperformed AAV2-WT, achieving up to 90% higher transduction efficiency at a multiplicity of infection of 2 × 10³ VG/cell. The S489A mutant consistently ranked among the top performers, with nearly 8-fold greater EGFP expression compared to wild-type.
In vivo evaluation was conducted in C57BL/6 mice receiving tail vein injections of 5 × 10¹⁰ VG per animal. Four weeks post-injection, hepatic tissues were analyzed for transgene expression. Fluorescence microscopy revealed strong EGFP signal in livers from animals treated with S/T/K mutants, particularly S489A, S498A, K532R, and K544R. Quantitative PCR confirmed up to 4.9-fold higher vector genome copy numbers per diploid genome in mutant-treated groups versus AAV2-WT controls. Real-time RT-PCR further demonstrated a 14-fold increase in EGFP transcript levels, indicating robust and sustained expression.
Crucially, immune profiling revealed a dramatic reduction in neutralizing antibody formation. Serial dilution assays showed that the S489A mutant induced approximately 8-fold lower neutralizing antibody titers than AAV2-WT. This suggests that the mutation alters capsid epitopes recognized by B cells and antibodies, potentially reducing cross-reactivity with wild-type vectors. Notably, despite its enhanced transduction, the S489A vector elicited no significant inflammatory response, with histological examination showing normal liver architecture and median inflammation scores of 0–1 across all groups.PMID:35061220
Further mechanistic studies using an in vitro ubiquitination assay demonstrated that the K532R mutant exhibited markedly reduced ubiquitin conjugation compared to both AAV2-WT and AAV5-WT. This supports the idea that lysine mutations directly interfere with the ubiquitin ligase machinery, leading to prolonged cytoplasmic survival and improved nuclear entry of viral genomes.
These findings highlight a dual advantage of engineered AAV2 vectors: enhanced transduction efficiency due to evasion of proteasomal degradation and reduced immunogenicity due to altered capsid antigenicity. By combining these benefits, the modified vectors enable effective gene delivery at significantly lower doses, minimizing the risk of immune activation while maximizing therapeutic output. This strategy represents a major step forward in developing safer, more effective AAV-based therapies for inherited liver diseases such as hemophilia B, where durable expression and repeat dosing are critical for long-term success.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
Hepatocellular carcinoma (HCC) remains a major global health challenge, with limited effective systemic therapies. The development of targeted agents inhibiting tumor angiogenesis has emerged as a promising strategy, particularly those directed against vascular endothelial growth factor (VEGF), a key driver of neovascularization in HCC. Drugs such as sorafenib and lenvatinib—both multi-kinase inhibitors targeting VEGF receptors—have become standard treatments for advanced HCC. However, patient responses vary widely, and biomarkers capable of predicting therapeutic efficacy are urgently needed.
Several clinical trials have investigated the relationship between baseline VEGF expression levels in tumor tissue and response to anti-angiogenic therapy. While some studies reported that high VEGF expression correlates with better outcomes, others found no association or even worse survival in VEGF-positive patients. This inconsistency may stem from differences in study design, treatment regimens, assessment methods, and patient selection. To resolve this controversy, we conducted a meta-analysis of available clinical trials evaluating the impact of VEGF expression on treatment response and survival outcomes in patients with advanced HCC receiving anti-angiogenic therapy.
We included nine randomized controlled trials and cohort studies involving 1,042 patients treated with sorafenib, lenvatinib, or other VEGF-targeted agents. All studies provided data on tumor VEGF expression assessed via immunohistochemistry (IHC) or RT-PCR, along with objective response rates (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Data were extracted independently by two reviewers, and hazard ratios (HRs) and odds ratios (ORs) were calculated using published survival curves or directly reported values.
Our analysis revealed that patients with high VEGF expression had significantly higher objective response rates (OR = 2.2-Cyanothiazole Autophagy 35, 95% CI: 1.67–3.30; P < 0.001) and improved disease control rates (OR = 2.D-Panthenol custom synthesis 18, 95% CI: 1.54–3.08; P < 0.001) compared to those with low expression. These findings suggest that tumors with elevated VEGF levels may be more dependent on angiogenic signaling and thus more susceptible to VEGF inhibition.PMID:35076956
Moreover, high VEGF expression was associated with longer progression-free survival (HR = 0.69, 95% CI: 0.56–0.85; P = 0.001) and improved overall survival (HR = 0.76, 95% CI: 0.62–0.94; P = 0.012). Subgroup analyses showed consistent results across different drugs, including sorafenib and lenvatinib, indicating that the predictive value of VEGF is not drug-specific but rather reflects underlying tumor biology.
Sensitivity analyses excluding individual studies did not alter the direction or significance of the results, confirming robustness. No significant publication bias was detected using Begg’s and Egger’s tests (P > 0.05), suggesting that the findings reflect the true effect size rather than selective reporting.
Notably, the benefit of VEGF positivity was most pronounced in patients with moderate to high expression levels, while those with very low or absent expression derived minimal benefit. This supports the concept of “angiogenic dependency” where tumors reliant on VEGF pathways respond better to targeted inhibition.
In conclusion, this meta-analysis provides strong evidence that high pre-treatment VEGF expression in hepatocellular carcinoma is a favorable predictor of response to anti-angiogenic therapy, including improved objective response, disease control, and prolonged survival. These findings underscore the potential of VEGF as a companion diagnostic to guide personalized treatment decisions. Future prospective trials should validate these results in larger cohorts and explore whether combining VEGF status with other molecular markers can further refine patient selection for anti-angiogenic therapies.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
Nemaline myopathy (NM) is a genetically heterogeneous congenital myopathy defined by muscle weakness and the presence of nemaline bodies—rod-like structures derived from Z-disk abnormalities in skeletal muscle fibers. While mutations in five genes encoding thin filament components have been established as causes of NM, this study identifies a sixth: CFL2, which encodes cofilin-2, a key regulator of actin dynamics in skeletal muscle. A homozygous c.103G>A mutation in CFL2 was identified in two affected siblings from a consanguineous Middle Eastern family. The mutation results in an alanine-to-threonine substitution at residue 35 (A35T), located near a nuclear localization signal within a highly conserved region of the protein.
Clinical presentation in both patients included neonatal hypotonia, delayed motor development, recurrent falls, and progressive ambulatory impairment. The elder sister, aged 16, walks short distances but uses a wheelchair outdoors. The younger sibling, the proband, was diagnosed with NM at age 2 after a muscle biopsy revealed nemaline bodies, occasional minicores, and concentric laminated bodies. Notably, no significant facial weakness or foot drop was observed, distinguishing the phenotype from some other forms of NM.
Histopathological analysis confirmed the presence of nemaline bodies on Gomori trichrome staining and minicores on NADH-tetrazolium reductase staining. Electron microscopy revealed unstructured minicores and concentric laminated bodies, suggesting distinct ultrastructural abnormalities. Immunofluorescence using anti-a-actinin-2 antibodies showed that nemaline bodies were positive for this Z-disk protein. Phalloidin staining demonstrated abnormal F-actin accumulations in 4% of myofibers, colocalizing with sarcomeric actin, indicating a primary defect in actin organization.
Despite normal ACTA1 sequencing, the presence of actin filament aggregates pointed toward a broader actinopathy. Quantitative analysis revealed that cofilin-2 levels were markedly reduced in the proband’s muscle tissue. Two-dimensional SDS-PAGE and immunoblotting confirmed a significant decrease in unphosphorylated cofilin-2, with no detectable phosphorylated form. Paradoxically, CFL2 mRNA levels were elevated 4- to 20-fold compared to controls, implicating post-transcriptional mechanisms such as protein instability or degradation.
To assess the functional impact of the A35T mutation, wild-type and mutant cofilin-2 proteins were expressed in both mammalian and bacterial systems. In eukaryotic cells, both proteins localized normally and formed cytoplasmic and nuclear rods upon overexpression. However, in E. coli, the A35T variant showed severe solubility defects—while equal amounts of protein were present in total lysates, the mutant failed to purify under standard conditions. Only after treatment with 6 M urea was the mutant protein recovered, indicating aggregation due to misfolding.
Structural modeling based on chicken cofilin-2 revealed that the T35 side chain clashed sterically with I55, disrupting the β-sheet structure essential for stability.Tributyltetradecyl phosphonium Biochemical Assay Reagents This predicted conformational change supports the hypothesis that the A35T mutation destabilizes the tertiary structure, leading to premature degradation and functional deficiency.Copper(II) perchlorate hexahydrate Biological Activity
The accumulation of F-actin in nemaline bodies, minicores, and laminated bodies likely stems from impaired actin depolymerization due to cofilin-2 deficiency.PMID:34634487 This study provides strong genetic and biochemical evidence linking CFL2 mutations to a distinct form of congenital myopathy characterized by multiple pathological features. It also highlights the importance of cofilin-2 in maintaining sarcomeric integrity and suggests that its dysfunction may underlie a subset of NM cases previously attributed to nonspecific pathology. Future research should focus on identifying additional CFL2 mutations and exploring targeted therapies aimed at restoring actin homeostasis.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
Methadone’s ability to inhibit chloride currents in intestinal epithelial cells has been linked to its interference with lubiprostone-mediated activation of ClC-2 channels. This study focused on elucidating the molecular mechanism underlying methadone’s selective inhibition of recombinant human ClC-2 (hClC-2) channels expressed in HEK293EBNA cells, a high-expression system enabling robust electrophysiological characterization. Whole-cell patch-clamp recordings revealed that hClC-2 channels exhibit time-dependent, voltage-activated chloride currents with inward rectification and sensitivity to CdCl₂, confirming functional expression.
Methadone inhibited both control and lubiprostone-stimulated hClC-2 currents in a concentration-dependent manner, with half-maximal inhibitory concentrations (IC₅₀) of 100 nM for baseline currents and 200–230 nM for activated currents. Notably, methadone’s effect was significantly more pronounced when added prior to patching (66.1% inhibition) than after (28.Anti-Mouse CD25 Antibody Immunology/Inflammation 7%), indicating that it may access intracellular sites or modulate channel conformation before membrane sealing. This suggests methadone does not act solely by blocking open channels but potentially alters channel gating or trafficking.
The involvement of protein kinase A (PKA) signaling was further explored using myristoylated PKA inhibitor (mPKI), a specific inhibitor of PKA activity. Forskolin/IBMX-induced activation of hClC-2 currents was abolished in the presence of mPKI, confirming that this pathway relies on PKA-mediated phosphorylation.Encenicline Purity & Documentation However, lubiprostone-stimulated currents remained unaffected by mPKI, indicating that lubiprostone activates hClC-2 through a PKA-independent mechanism. Despite this, methadone still inhibited both forskolin/IBMX- and lubiprostone-activated currents even in the presence of mPKI, demonstrating that methadone’s action is downstream of PKA activation and not dependent on the same signaling cascade.PMID:35105593
In contrast, methadone had no effect on forskolin/IBMX-stimulated chloride currents in hCFTR-expressing HEK293 cells, highlighting the specificity of its action toward ClC-2. These findings suggest that methadone does not broadly impair chloride transport but selectively targets ClC-2 function, likely through direct interaction with the channel protein or modulation of its regulatory environment.
The lack of naloxone reversal and the high IC₅₀ values compared to mu-opioid receptor affinity further support a non-receptor-mediated mechanism. Given that methadone also inhibits other ion channels such as L-type Ca²⁺ channels and hERG K⁺ channels via direct binding, it is plausible that it interacts with structural motifs within the ClC-2 channel, possibly near the voltage sensor or pore region. While direct binding studies are needed, the current data strongly indicate that methadone disrupts ClC-2 function independently of agonist stimulation or classical opioid receptor pathways.
These results provide a mechanistic basis for the clinical observation that lubiprostone fails to alleviate constipation in patients on methadone therapy. By inhibiting ClC-2-mediated chloride secretion, methadone counteracts the intended therapeutic effect of lubiprostone, underscoring the importance of considering pharmacological interactions between opioids and gastrointestinal ion channels in treatment planning.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com